Finally, by examining patients with the three diseases combined diabetes, hypertension, and hypertension-diabetes after SARS-CoV-2 infection, we propose that activated endothelial cells may be a potential bridge to fibrosis, as well as suggesting that the preference of anti-hypertensive drug targets and the influence of entry factors on the combined three diseases is not a traditional ACE2, while proposing that Nintedanib is a superior choice for late fibrotic sequelae. This evidence concerns the gene ACE2 and hypertensive disorder.